- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02333461
Evaluation of Botanicals for Mechanisms Related to Appetite and Fat Metabolism
Study to Evaluate Botanicals for Mechanisms Related to Appetite and Fat Metabolism in Healthy, Overweight and Obese Individuals
Excess caloric consumption, particularly from inexpensive, energy dense foods that are high in fat and refined carbohydrates, is a major driver of the global obesity epidemic. Dietary supplements that promote reduced intake of energy dense foods and/or impact the absorption and metabolism of fat and carbohydrates in the body can be used to help consumers control their weight. We identified two separate mechanistic approaches to target these effects.
Diacylglycerol acyltransferase-1 (DGAT-1) is an enzyme involved in the formation of dietary fat into circulating triglycerides within the body. Once dietary fat is digested and absorbed, the resulting fatty acids are re-esterified into triglycerides. Inhibition of DGAT-1 results in delayed and decreased re-esterification of dietary fats into circulating triglycerides. It is hypothesized that this effect may lead to decreased deposition of excess dietary fat as adipose tissue, possibly due to increased fatty acid oxidation in the enterocytes.
Ghrelin is a hormone that is known to stimulate appetite in humans. When calorie dense fatty foods are sensed in the stomach, ghrelin is acylated and activated via ghrelin O-acyltransferase (GOAT). The activation step attaches a medium chain fatty acid to the ghrelin molecule that enables it to transmit a signal in the brain that triggers eating and fat storage in adipose tissue. Interfering with the GOAT pathway will inhibit ghrelin activation and possibly diminish food intake and lipid storage. This concept is supported by animal studies in which weight gain in a high fat diet model is prevented when GOAT is inhibited.
Our objective was to determine whether botanicals demonstrating in vitro DGAT-1 and GOAT inhibition have similar mechanistic effects in the human body. Based on the results of this study, prototype formulas may be developed and clinically- tested for outcomes related to weight management.
Study Overview
Status
Conditions
Detailed Description
Excess caloric consumption, particularly from inexpensive, energy dense foods that are high in fat and refined carbohydrates, is a major driver of the global obesity epidemic. Dietary supplements that promote reduced intake of energy dense foods and/or impact the absorption and metabolism of fat and carbohydrates in the body can be used to help consumers control their weight. We identified two separate mechanistic approaches to target these effects.
Diacylglycerol acyltransferase-1 (DGAT-1) is an enzyme involved in the formation of dietary fat into circulating triglycerides within the body. Once dietary fat is digested and absorbed, the resulting fatty acids are re-esterified into triglycerides. Inhibition of DGAT-1 results in delayed and decreased re-esterification of dietary fats into circulating triglycerides. It is hypothesized that this effect may lead to decreased deposition of excess dietary fat as adipose tissue, possibly due to increased fatty acid oxidation in the enterocytes.
Ghrelin is a hormone that is known to stimulate appetite in humans. When calorie dense fatty foods are sensed in the stomach, ghrelin is acylated and activated via ghrelin O-acyltransferase (GOAT). The activation step attaches a medium chain fatty acid to the ghrelin molecule that enables it to transmit a signal in the brain that triggers eating and fat storage in adipose tissue. Interfering with the GOAT pathway will inhibit ghrelin activation and possibly diminish food intake and lipid storage. This concept is supported by animal studies in which weight gain in a high fat diet model is prevented when GOAT is inhibited.
Ghrelin levels are positively associated with stress, sleep deprivation, and caloric restriction. Weight loss induced by exercise does not have the same positive association with ghrelin levels that caloric restriction alone has. Ghrelin levels are influenced by diet composition, however, the results vary considerably between trials.
Over 160 botanical extracts from our internal ingredient library were screened at a single concentration for inhibition of both DGAT-1 and GOAT. Botanicals that were identified as having at least 75% activity were then titrated to identify those with IC50 values < 25 g/ml or less. We narrowed our list of viable ingredients by looking at those with activity in both the DGAT-1 and GOAT in vitro enzyme bioassay models. The top performing botanicals were then evaluated in a cellular model for DGAT-1 inhibition. Those with the highest inhibition activity in this model were considered lead candidates. A preliminary literature search was conducted and the final filter included factors such as cost and regulatory acceptability which results in the four ingredients being tested in the current clinical protocol.Our objective was to determine whether these four ingredients have similar mechanistic effects in the human body.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Overweight/obese (BMI of 25-35 kg/m2) men and women.
- Participant must be 18-70 years of age.
- Considered healthy with no evidence of chronic diseases.
- Willing to maintain a consistent diet and exercise pattern throughout the duration of the study.
- Willing to consume a dairy and egg-based fat challenge meal twice, at start and end of study (V2 & V3).
Exclusion Criteria:
- History of allergic reaction to fruit, dairy or egg products.
- Current smoker or history of tobacco use within the past year.
- Use of dietary supplements within 1 week prior to Visit 2 and unwilling to refrain from use through the duration of the trial. Supplements include any vitamins, minerals, and herbal products, including herbal drinks.
- Use of fish oil supplements within the past 8 weeks.
- Consumption of fatty fish one or more times per week within the past 8 weeks (e.g., mackerel, salmon, trout, canned albacore tuna, sardines, haddock, cod, hake, halibut, shrimp, sole, flounder, perch, black bass, swordfish, oysters, Alaskan king crab).
- Presence of cardiovascular disease, cancer, diabetes mellitus, inflammatory bowel disease, lactose intolerance, or any other chronic health condition identified from the findings of the interview.
- History of gastric bypass or other surgery that physically alters the gastrointestinal tract.
- Blood pressure greater > 140 mm Hg systolic or > 90 mm Hg diastolic during seated, resting measurement on two consecutive occasions during visit 1.
- Fasting serum triglycerides > 200 mg/dl.
- Use of lipid lowering medications or dietary supplements.
- Use of blood pressure lowering medications or dietary supplements.
- Use of Coumadin, aspirin, or other medications that influence hemostasis.
- Daily use of low dose (< 81 mg) aspirin is allowed.
- Use of antibiotics within the past week.
- Chronic or therapeutic use of antacids, H2 agonists, and proton pump inhibitors.
- Use of selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, and/or any other drug with vasoconstricting properties.
- Pregnant or lactating women, or women of child-bearing potential unwilling to use a medically approved form of birth control.
- History, in the past year, of current abuse of drugs or alcohol, or intake > 14 alcoholic beverages per week.
- Participation in another clinical trial within 28 days of enrollment into the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
333 mg capsule comprised of silicified microcrystalline cellulose, magnesium stearate, modified cellulose gum, silicon dioxide, dextrose, corn starch, and caramel color.
Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
|
Participants were randomly assigned to receive one of four botanical interventions or placebo.
|
Experimental: Apple
333 mg capsule comprised of apple peel extract (115:1, standardized to 80% polyphenol and 5% phlorizin).
Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
|
Participants were randomly assigned to receive one of four botanical interventions or placebo.
|
Experimental: Grape
333 mg capsule comprised of grape extract (8000:1, standardized to 75% total polyphenol, 50% oligomeric proanthocyanidin).
Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
|
Participants were randomly assigned to receive one of four botanical interventions or placebo.
|
Experimental: Red Raspberry
333 mg capsule comprised of red raspberry leaf extract (4:1, standardized to 6% ellagic acid).
Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
|
Participants were randomly assigned to receive one of four botanical interventions or placebo.
|
Experimental: Apricot/Nectarine
333 mg capsule comprised of apricot/nectarine extract (40:1, standardized to 50% polyphenol).
|
Participants were randomly assigned to receive one of four botanical interventions or placebo.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Serum triglyceride response (area under the curve = AUC) following consumption of a standardized high fat meal challenge.
Time Frame: Six hours
|
Six hours
|
Plasma acylated ghrelin response (AUC) following consumption of a standardized high fat meal challenge
Time Frame: Three hours
|
Three hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum concentration (Cmax) for serum triglycerides following consumption of a standardized high fat meal challenge
Time Frame: Six hours
|
Six hours
|
Time to maximum concentration (Tmax) for serum triglycerides following consumption of a standardized high fat meal challenge
Time Frame: Six hours
|
Six hours
|
Cmax for plasma acylated ghrelin following consumption of a standardized high fat meal challenge
Time Frame: Three hours
|
Three hours
|
Tmax for plasma acylated ghrelin following consumption of a standardized high fat meal challenge
Time Frame: Three hours
|
Three hours
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BURN CURB POM-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Fundació Sant Joan de DéuNot yet recruitingObesity, Childhood | Obesity, AdolescentSpain
-
Consorcio Centro de Investigación Biomédica en...Maimónides Biomedical Research Institute of Córdoba; Instituto de Salud Carlos... and other collaboratorsActive, not recruiting
-
University of HoustonBaylor College of MedicineCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States